Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of MRT5500 in Healthy Adults
NCT04798027Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of MRT5500 in coronavirus disease 2019 (COVID-19) (9 cohorts), sponsored by Sanofi. Primary endpoints: Number of Participants Reporting Immediate Unsolicited Adverse Events, Number of Participants With Solicited Injection Site Reactions and 13 more. Started Mar 2021; status: terminated.
02
Drugs
MRT5500
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04798027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04798027.